media – Page 10 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】Is a ventilator the same as an oxygen generator? What’s the difference?

Drugdu.com expert’s response: Ventilators and oxygen concentrators are different, with significant disparities in their functional positioning, working principles, applicable populations, output gases, usage scenarios, and equipment structures, as detailed below: Functional Positioning Ventilator: Primarily used to assist or replace a patient’s respiratory function, helping those unable to breathe autonomously or with inadequate respiratory function to complete breathing movements and maintain airway patency and respiratory function. It is suitable for patients with respiratory failure, apnea, and other respiratory dysfunctions. Oxygen Concentrator: Mainly used to increase the oxygen concentration in inhaled air, providing high-concentration oxygen to hypoxic patients to improve their hypoxic state. It is suitable for individuals who are hypoxic but have basically normal respiratory function, such as patients with chronic obstructive pulmonary disease (COPD) and heart failure. Working Principles Ventilator: It pushes air into the lungs through mechanical force, simulating the human breathing process and regulating the rhythm and depth ...
- Source: drugdu
- 101
- April 17, 2026
Maiweijian® (Denosumab Injection) New Indication Supplemental Application Accepted by NMPA

Maiwei Biopharmaceutical (688062.SH), an innovative biopharmaceutical company with a full-industry chain layout, announced that the National Medical Products Administration (NMPA) has accepted the supplemental application for adding indications for Maiweijian® (denosumab injection, R&D code: 9MW0321), independently developed by its wholly-owned subsidiary Taikang Biopharmaceutical , for the treatment of bone metastases of solid tumors and multiple myeloma (for the treatment of patients with bone metastases of solid tumors or multiple myeloma, to delay or reduce the risk of bone-related events (pathological fractures, spinal cord compression, bone radiotherapy or bone surgery)). Maiweijian® is the first denosumab biosimilar (120mg) approved for marketing in China . It was first approved in March 2024 for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection would result in severe functional impairment, including adults and skeletally mature (defined as at least one mature long bone and a weight ≥45kg) adolescents. In ...
- Source: drugdu
- 82
- April 16, 2026
The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders.

Luye Pharma (02186.HK) issued a voluntary announcement stating that its independently developed innovative drug…The first subject has been enrolled in the Phase II clinical trial in China of LY03017 for the treatment of psychotic disorders in Alzheimer’s disease. LY03017 is a new-generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, with target indications including psychotic disorders in Alzheimer’s disease, psychotic disorders in Parkinson’s disease, and negative symptoms of schizophrenia. This Phase II clinical trial is a randomized, double-blind, parallel, placebo-controlled study designed to evaluate the preliminary efficacy and safety of LY03017 in treating hallucinations and delusions associated with Alzheimer’s disease; the drug has previously been approved for clinical trials in the United States. Background: Of the approximately 57 million dementia patients worldwide, 60% to 70% have Alzheimer’s disease, of whom 25% to 50% experience psychotic symptoms. Currently, there are no approved drugs worldwide for this indication. The Phase I clinical trial of ...
- Source: drugdu
- 77
- April 16, 2026
The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders.

Nanfang Finance News, April 15th – Luye Pharma (02186.HK) issued a voluntary announcement stating that its independently developed innovative drug…The first subject has been enrolled in the Phase II clinical trial in China of LY03017 for the treatment of psychotic disorders in Alzheimer’s disease. LY03017 is a new-generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, with target indications including psychotic disorders in Alzheimer’s disease, psychotic disorders in Parkinson’s disease, and negative symptoms of schizophrenia. This Phase II clinical trial is a randomized, double-blind, parallel, placebo-controlled study designed to evaluate the preliminary efficacy and safety of LY03017 in treating hallucinations and delusions associated with Alzheimer’s disease; the drug has previously been approved for clinical trials in the United States. Background: Of the approximately 57 million dementia patients worldwide, 60% to 70% have Alzheimer’s disease, of whom 25% to 50% experience psychotic symptoms. Currently, there are no approved drugs worldwide for this indication. ...
- Source: drugdu
- 69
- April 16, 2026
Its subsidiary’s Phase III clinical trial of “Vitamettrazil” has completed the enrollment of the first patient.

On April 15, China Biopharmaceutical (01177) issued an announcement stating that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has independently developed a Class 1 innovative drug.Vitacoltobayumab (development code: LM-302) is undergoing a Phase III registration clinical trial in combination with a PD-1 monoclonal antibody as first-line treatment for CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, and the first patient has been successfully enrolled. LM-302 has been included in the Breakthrough Therapy Program by the China National Medical Products Administration for multiple indications and has received orphan drug designation from the U.S. Food and Drug Administration. https://finance.eastmoney.com/a/202604153705999476.html
- Source: drugdu
- 70
- April 16, 2026
A multi-billion dollar market is fiercely competitive, with Huadong Medicine applying for marketing approval of its megglutinin weight loss product.

On the evening of April 14, Huadong Medicine (000963) issued an announcement stating that its wholly-owned subsidiary, Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co., Ltd., received an “Acceptance Notice” issued by the National Medical Products Administration (NMPA) for the acceptance of its application for marketing authorization of Smegglutide injection, which is applicable to long-term weight management in adult patients based on diet control and increased physical activity. Previously, Huadong Medicine’s application for marketing authorization of its semaglutide injection for the hypoglycemic indication had been formally accepted by the National Medical Products Administration (NMPA). The acceptance of its application for the weight loss indication signifies that the product is poised to further expand its clinical application scenarios, meeting diverse market demands while gradually unlocking its long-term growth potential in chronic disease management and weight control. Smegglutide injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. ...
- Source: drugdu
- 88
- April 16, 2026
Another domestically developed AD drug successfully completed Phase III trials.

Recently, Zaijing Pharmaceuticals announced that its independently developed Class 1 new drug, gecacitinib hydrochloride tablets (formerly known as jactinib hydrochloride tablets), has met its primary efficacy endpoint in a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial for the treatment of moderate to severe atopic dermatitis in adult patients , demonstrating statistical significance (p<0.0001). This signifies another major breakthrough for Zaijing Pharmaceuticals in the field of autoimmune diseases. Gecacitinib is a novel dual inhibitor of JAK and ACVR1 independently developed by Zaijing Pharmaceuticals , and is classified as a Class 1 new drug. This drug received NMPA approval in May 2025 for the treatment of intermediate- and high-risk myelofibrosis, making it the first domestically produced innovative JAK inhibitor approved for the treatment of myelofibrosis. In addition, the NMPA has accepted the NMPA application for the indication of severe alopecia areata and is currently under review and approval; the three clinical ...
- Source: drugdu
- 71
- April 16, 2026
The Shanxi Medical Device Exhibition (CWMEE)

Organiser：Shanxi Medical Device Industry Association Time：May 15 – 17, 2026 Address：No. 6, Changfeng West Street, Taiyuan Exhibition hall：Taiyuan Jinyang Lake International Convention and Exhibition Center Product range: Medical Imaging: 5G remote solutions, precision imaging, intelligent imaging, smart hospital systems, etc. Medical Electronics: critical care medicine equipment, blood transfusion, dialysis, and extracorporeal circulation devices, maternal and child health and tumor treatment equipment, electronic therapeutic devices, etc. In Vitro Diagnostics: molecular diagnostics, point-of-care testing (POCT), immunoassays, cancer screening, biochemical testing, laboratory overall solutions, biological sample storage and transportation, home rapid testing, etc. Medical Optics: 5G technology-based surgical endoscopy solutions, brand-new high-definition endoscopes, capsule endoscopes, laser therapy devices, etc. Medical Consumables: high-value consumables, surgical consumables, nursing consumables, protective consumables, etc. Disinfection and Infection Control: disinfection supply centers, endoscope cleaning centers, infant bathing centers, air disinfection equipment, third-party disinfection outsourcing Rehabilitation Medicine: rehabilitation training equipment, functional assessment devices, training room auxiliary devices, diagnostic ...
- Source: drugdu
- 99
- April 16, 2026
Henlius’s cetuximab biosimilar HLX05-N received approval in China for clinical trials.

On April 14, 2026, Henlius Biotech (2696.HK) announced that its Investigational New Drug (IND) application for HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection), a cetuximab biosimilar developed by the company, was approved by the National Medical Products Administration (NMPA) of China for the treatment of metastatic colorectal cancer. Epidermal growth factor receptor (EGFR) belongs to the ErbB family of cell surface erythroleukemia virus oncogene homologs with tyrosine kinase activity. It is a transmembrane glycoprotein widely expressed in normal epithelial cells and tumor tissues such as colorectal cancer and head and neck cancer. EGFR-mediated signaling pathways regulate tumor growth through multiple pathways and play a key regulatory role in the proliferation, differentiation, survival, and metastasis of tumor cells. Therefore, it is considered an important therapeutic target for related tumors. Cetuximab specifically binds to EGFR on the cell surface. On one hand, it competitively inhibits the binding of ligands such as ...
- Source: drugdu
- 79
- April 15, 2026
Huadong Medicine’s application for marketing authorization of megglutide injection for remanufactured fluids has been accepted by the NMPA.

On April 14, 2026, Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co., Ltd. (hereinafter referred to as “Jiangdong Company”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (hereinafter referred to as “the Company”), received the “Acceptance Notice” issued by the National Medical Products Administration (NMPA), in which the marketing authorization application for Smegglutide injection (research code: HDM1702) submitted by Jiangdong Company was accepted. The indication for this application is: This product is suitable for long-term weight management in adult patients based on diet control and increased physical activity, with an initial body mass index (BMI) meeting the following criteria: ≥30kg/m2 ( obese), or ≥27kg/m2 to <30kg/m2 ( overweight) and having at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Regarding Smegglutide injection Smegglutide injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Clinically, it is mainly used for ...
- Source: drugdu
- 74
- April 15, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.